What Bruker’s recent performance means for investors

Bruker (BRKR) has drawn attention after a mixed stretch for the stock, with a gain of about 19% over the past week and an increase of roughly 15% over the past month.

That recent burst of momentum, with an 18.9% 7 day share price return and a 15.1% 30 day share price return to US$43.27, contrasts with a softer year to date share price return and a 3 year total shareholder return that has been weak. As a result, sentiment looks to be recovering from a low base.

If Bruker’s recent rebound has you looking around the sector, this is a good moment to scan 32 healthcare AI stocks as another way to find potential opportunities in similar areas.

So with Bruker trading at US$43.27 and sitting at roughly a 13% discount to both its analyst price target and one intrinsic estimate, should you view this as undervalued or assume the market is already accounting for future growth in the current price?

Most Popular Narrative: 10% Undervalued

Bruker’s most followed narrative pegs fair value at about $47.86 per share, compared with the recent close at $43.27, putting the spotlight firmly on what needs to go right to support that gap.

The expected stabilization and eventual recovery of research and biopharma funding in both the US and China, along with global settlements on tariffs, could trigger a rebound in demand for Bruker's advanced life science and drug discovery instruments, which would support renewed top-line revenue growth post-2025.

Bruker's expanded cost reduction program (targeting $100–$120 million of annualized savings, mainly realized in FY26) is set to drive at least 300 basis points of operating margin expansion and double-digit EPS growth, even in a flat to muted revenue environment, which would improve net margins and earnings quality.

Want to see what is baked into that fair value? The narrative leans heavily on a sharp swing into profitability and a richer future earnings multiple. Curious how revenue, margins and discount rate all link together to support that $47.86 figure?

Result: Fair Value of $47.86 (UNDERVALUED)

However, you also need to weigh ongoing funding pressure in US and China research markets, along with helium-related input cost risks that could challenge Bruker in meeting these assumptions.

Next Steps

All of this mixed sentiment only matters if you use it to sharpen your own view. Move quickly and weigh both sides with the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing stronger setups, better income, and quieter risks that could suit your goals far more closely.

• Target potential mispricings by scanning a curated list of quality companies trading below intrinsic value using the 48 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with robust, higher yielding payouts through the 12 dividend fortresses.
• Dial down risk by hunting for companies with resilient financials using the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.